- Home
- XOMAP vs UONEK Comparison
XOMAP vs UONEK Comparison
Compare XOMAP & UONEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XOMAP
- UONEK
- Stock Information
- Founded
- XOMAP N/A
- UONEK 1980
- Country
- XOMAP United States
- UONEK United States
- Employees
- XOMAP 13
- UONEK N/A
- Industry
- XOMAP Biotechnology: Pharmaceutical Preparations
- UONEK Broadcasting
- Sector
- XOMAP Health Care
- UONEK Consumer Discretionary
- Exchange
- XOMAP Nasdaq
- UONEK Nasdaq
- Market Cap
- XOMAP N/A
- UONEK N/A
- IPO Year
- XOMAP N/A
- UONEK N/A
- Fundamental
- Price
- XOMAP $25.95
- UONEK $0.54
- Analyst Decision
- XOMAP
- UONEK
- Analyst Count
- XOMAP 0
- UONEK 0
- Target Price
- XOMAP N/A
- UONEK N/A
- AVG Volume (30 Days)
- XOMAP N/A
- UONEK 28.3K
- Earning Date
- XOMAP N/A
- UONEK 06-09-2025
- Dividend Yield
- XOMAP N/A
- UONEK N/A
- EPS Growth
- XOMAP N/A
- UONEK N/A
- EPS
- XOMAP N/A
- UONEK N/A
- Revenue
- XOMAP N/A
- UONEK $449,674,000.00
- Revenue This Year
- XOMAP N/A
- UONEK N/A
- Revenue Next Year
- XOMAP N/A
- UONEK N/A
- P/E Ratio
- XOMAP N/A
- UONEK N/A
- Revenue Growth
- XOMAP N/A
- UONEK N/A
- 52 Week Low
- XOMAP N/A
- UONEK $0.50
- 52 Week High
- XOMAP N/A
- UONEK $2.07
- Technical
- Relative Strength Index (RSI)
- XOMAP 52.85
- UONEK 36.30
- Support Level
- XOMAP $24.96
- UONEK $0.49
- Resistance Level
- XOMAP $26.10
- UONEK $0.75
- Average True Range (ATR)
- XOMAP 0.38
- UONEK 0.05
- MACD
- XOMAP 0.03
- UONEK -0.01
- Stochastic Oscillator
- XOMAP 76.74
- UONEK 19.23
About XOMAP XOMA Corporation 8.625% Series A Cumulative Perpetual Preferred Stock
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.